DAMORA THERAPEUTICS, INC.
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-31.2M | $-27.8M | $-3.1M | $-3.4M | $-2.5M | $-3.9M | $-5.3M | $-5.5M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | — | $5.0K | $6.0K | $6.0K | $5.0K | $6.0K | $5.0K | $5.0K |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | — | $3.1M | — | — | $179.0K | — | — | $1.4M |
| Net Cash from Operating Activities | $-21.9M | $-20.6M | $-2.6M | $-2.2M | $-2.4M | $-3.7M | $-4.1M | $-5.9M |
| Investing Activities | ||||||||
| Capital Expenditures | — | — | — | — | — | — | — | — |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | — | — | — | — | — | — | — | $5.7M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | — | $295.9M | — | — | — | — | — | — |
| Net Change in Cash | — | — | — | — | — | — | — | — |
| Free Cash Flow | — | — | — | — | — | — | — | — |